<DOC>
	<DOCNO>NCT02437812</DOCNO>
	<brief_summary>Initially , prospect metformin neoplastic treatment consider malignancy prostate , colon pancreas . However , select clinical study involve use metformin treatment ovarian cancer document improved survival rate . Since first line regimen demonstrate compel superiority management advance stage ovarian carcinoma , combination paclitaxel , carboplatin , metformin particular interest give triplet 's prospect achieve increase synergy without compromise patient tolerability .</brief_summary>
	<brief_title>Study Paclitaxel , Carboplatin Oral Metformin Treatment Advanced Stage Ovarian Carcinoma</brief_title>
	<detailed_description>A phase II , open-label , non-randomized , pilot study assess safety , toxicity , progression free survival advance stage ovarian carcinoma patient underwent treatment paclitaxel , carboplatin metformin . An estimated 30 patient require study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Female Gender Age great 18 year Advanced stage epithelial ovarian , fallopian tube , primary peritoneal cancer Adequate bone marrow function ECOG performance score 2 great Patients must able swallow oral medication . Subjects must NOT take metformin metformin past 6 month . Subjects diagnosis epithelial ovarian , fallopian tube peritoneal cancer low malignant potential ( borderline carcinoma ) Subjects concomitant malignancy previous malignancy within past three year , melanoma skin cancer except</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>